Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01401985 · ClinicalTrials.gov registry record · Phase 2
A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC)
A Phase 2 study of Opioid-induced Constipation, sponsored by Theravance Biopharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 95
- Enrollment target
- 1
- Study location
NCT01401985: Completed Phase 2 study of Opioid-induced Constipation, sponsored by Theravance Biopharma.
NCT01401985 is a Phase 2 study of Opioid-induced Constipation that has completed, run by Theravance Biopharma. The registered enrollment target is 95 participants, below the 7,213-participant average among 5 other Opioid-induced Constipation trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01401985, a Phase 2 study of Opioid-induced Constipation, has completed, sponsored by Theravance Biopharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 95 participants
- Enrollment target
- 1
- Study location
Study Summary
A Single-Blind, Pilot Study to Determine the Tolerability and Safety of TD-1211 in Subjects with Opioid-Induced Constipation
Conditions Studied
Interventions
- DRUG Placebo
- DRUG TD-1211
Study Locations (1)
California
- Theravance Biopharma Investigational Site - Pasadena
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2011-10 |
| Est. Completion | 2012-08 |
| Phase | Phase 2 |
What the finished NCT01401985 record still lists
NCT01401985 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 95 participants, a relatively small participant target, below the 7,213-participant average among 5 other Opioid-induced Constipation trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Opioid-induced Constipation appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01401985 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01401985 about?
NCT01401985 is a clinical study titled "A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC)". A Single-Blind, Pilot Study to Determine the Tolerability and Safety of TD-1211 in Subjects with Opioid-Induced Constipation
What is the current status of trial NCT01401985?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 95 participants. The study started on 2011-10. Estimated completion is 2012-08.
What conditions does trial NCT01401985 study?
This clinical trial studies the following conditions: Opioid-induced Constipation.
What interventions are being tested in trial NCT01401985?
The interventions under investigation include: Placebo (DRUG), TD-1211 (DRUG).
Who is sponsoring clinical trial NCT01401985?
This trial is sponsored by Theravance Biopharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01401985 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid-induced Constipation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation
RECRUITING
-
Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced Constipation
COMPLETED · Phase 3
-
Compassionate Use Study of Methylnaltrexone
COMPLETED · NA
-
Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness
COMPLETED · Phase 4
-
A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant Pain
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03339128 · 95 participants · Phase 2
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
- NCT03509961 · 95 participants · Phase 2
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- NCT03694756 · 95 participants · NA
TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer
- NCT04206215 · 95 participants · NA
Noninvasive Brain Stimulation for Treating Carpal Tunnel Syndrome
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia